Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pharvaris said its phase 3 RAPIDe-3 study of deucrictibant IR in hereditary angioedema met its primary endpoint and all 11 secondary endpoints. The company also said the drug was under FDA and EMA review.
PHVS reports Phase 3 study results highlighting deucrictibant’s rapid and sustained efficacy in treating HAE attacks, published in The Lancet.